RAYMOND JAMES & ASSOCIATES - INTELLIA THERAPEUTICS INC ownership

INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 279 filers reported holding INTELLIA THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.98 and the average weighting 0.2%.

Quarter-by-quarter ownership
RAYMOND JAMES & ASSOCIATES ownership history of INTELLIA THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$3,300,306
+15.8%
104,374
+49.3%
0.00%
+50.0%
Q2 2023$2,851,174
+44.6%
69,916
+32.1%
0.00%0.0%
Q1 2023$1,972,254
+167.9%
52,918
+150.8%
0.00%
+100.0%
Q4 2022$736,179
-28.2%
21,100
+15.1%
0.00%0.0%
Q3 2022$1,026,000
+45.5%
18,331
+34.6%
0.00%0.0%
Q2 2022$705,000
-31.2%
13,614
-3.4%
0.00%0.0%
Q1 2022$1,025,000
-49.7%
14,100
-18.2%
0.00%
-50.0%
Q4 2021$2,038,000
-46.1%
17,234
-38.9%
0.00%
-33.3%
Q3 2021$3,781,000
-5.0%
28,186
+14.6%
0.00%
-25.0%
Q2 2021$3,982,000
+89.2%
24,594
-6.2%
0.00%
+100.0%
Q1 2021$2,105,000
+110.9%
26,227
+42.9%
0.00%
+100.0%
Q4 2020$998,000
+282.4%
18,347
+39.7%
0.00%
Q3 2020$261,000
-29.1%
13,130
-24.9%
0.00%
Q2 2020$368,000
+61.4%
17,484
-6.1%
0.00%
Q1 2020$228,000
-14.9%
18,614
+1.9%
0.00%
Q4 2019$268,000
+12.6%
18,264
+110.2%
0.00%
Q2 2018$238,000
-9.8%
8,688
-30.6%
0.00%
Q1 2018$264,00012,5270.00%
Other shareholders
INTELLIA THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Discovery Value Fund 561,561$17,756,5599.73%
MPM BioImpact LLC 544,639$17,221,4854.60%
Casdin Capital, LLC 1,178,075$37,250,7324.12%
HIMENSION CAPITAL (SINGAPORE) PTE. LTD. 1,145,091$36,207,7773.72%
Atlas Venture Associates IX, LLC 10,000$316,2002.69%
Deep Track Capital, LP 2,000,000$63,240,0002.44%
ARK Investment Management 9,948,629$314,575,6382.41%
Merlin Capital, Inc 18,526$585,7922.19%
Orchard Capital Management, LLC 159,155$5,032,4811.86%
TANG CAPITAL MANAGEMENT LLC 397,600$12,572,1121.77%
View complete list of INTELLIA THERAPEUTICS INC shareholders